<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6064">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01063595</url>
  </required_header>
  <id_info>
    <org_study_id>LAS-203</org_study_id>
    <nct_id>NCT01063595</nct_id>
  </id_info>
  <brief_title>A Trial to Investigate the Relative Efficacy, Safety, and Tolerability of Octaplas LG Versus Octaplas SD</brief_title>
  <official_title>A Comparative, Open-label, Randomized, Cross-over Phase I Trial in Healthy Volunteers to Investigate the Relative Efficacy, Safety and Tolerability of Octaplas LG™ vs. Octaplas®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Octapharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Octapharma</source>
  <oversight_info>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study was to compare the efficacy of Octaplas LG with Octaplas
      SD in terms of recovery of coagulation factors and other haemostatic parameters. The
      secondary objective of the study was to compare the safety and tolerability of Octaplas LG
      with Octaplas SD in terms of haematological and clinical chemistry parameters and adverse
      event monitoring.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Recovery of the Coagulation Factors I, II, V, VII, VIII, IX, X, and XI</measure>
    <time_frame>From 5 minutes after the end of plasmapheresis up to 2 hours after the end of study drug administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Recovery was defined as the maximum percentage change of the coagulation factor value measured 5 minutes after the end of plasmapheresis to the coagulation factor value measured at 15 minutes or 2 hours after the end of study drug administration. The coagulation parameters were measured by validated assays from blood samples obtained 5 minutes after the end of plasmapheresis and 15 minutes and 2 hours after the end of study drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recovery of the Haemostatic Parameters Prothrombin Time, Activated Partial Thromboplastin Time, and Protein C</measure>
    <time_frame>From 5 minutes after the end of plasmapheresis up to 2 hours after the end of study drug administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Recovery was defined as the maximum (minimum for activated partial thromboplastin time) percentage change of the haemostatic parameter value measured 5 minutes after the end of plasmapheresis to the haemostatic parameter value measured at 15 minutes or 2 hours after the end of study drug administration. The haemostatic parameters were measured by validated assays from blood samples obtained 5 minutes after the end of plasmapheresis and 15 minutes and 2 hours after the end of study drug administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of Plasmin Inhibitor</measure>
    <time_frame>From 30 minutes before plasmapheresis up to 24 hours after the end of plasmapheresis</time_frame>
    <safety_issue>No</safety_issue>
    <description>Values of plasmin inhibitor were measured by validated assays from blood samples obtained 30 minutes before plasmapheresis, 5 minutes after the end of plasmapheresis, 15 minutes and 2 hours after the end of study drug administration, and 24 hours and 7 days after initiation of plasmapheresis. The concentration of plasmin inhibitor is reported as the percentage of plasmin inhibition. A higher concentration of plasmin inhibitor results in a higher percentage of plasmin inhibition.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Comparison of Octaplas LG and Octaplas SD</condition>
  <arm_group>
    <arm_group_label>Octaplas LG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 1200 mL of Octaplas LG intravenously once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Octaplas SD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 1200 mL of Octaplas SD intravenously once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Octaplas LG</intervention_name>
    <description>Octaplas LG was composed of human coagulation-active plasma treated with solvent/detergent for 1-1.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. An additional manufacturing step, involving an affinity ligand gel, removed prion proteins. Octaplas LG was provided frozen in pyrogen free plastic bags.</description>
    <arm_group_label>Octaplas LG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Octaplas SD</intervention_name>
    <description>Octaplas SD was composed of human coagulation-active plasma treated with solvent/detergent for 4-4.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. Octaplas SD was provided frozen in pyrogen free plastic bags.</description>
    <arm_group_label>Octaplas SD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of understanding and complying with all aspects of the protocol.

          -  Signed Informed Consent.

          -  Capable of understanding the plasmapheresis information sheet and sign it.

          -  Healthy male or female volunteers, age 18 years or older.

          -  Women must have negative pregnancy test (human chorionic gonadotropin [HCG] based
             assay).

          -  Women must have sufficient methods of contraception (eg, intrauterine device, oral
             contraception, etc).

          -  No clinically relevant abnormalities in medical history and general physical
             examination.

          -  Standard health insurance.

        Exclusion Criteria:

          -  Pregnancy or lactation.

          -  Tattoos within the last 3 months.

          -  Subject was treated therapeutically with fresh frozen plasma, blood, or
             plasma-derived products within the last 6 months.

          -  Hypersensitivity to blood products or plasma proteins.

          -  History of angioedema.

          -  History of coagulation or bleeding disorder or any other known abnormality affecting
             coagulation, fibrinolysis, or platelet function.

          -  Any clinically significant abnormal laboratory values.

          -  IgA deficiency.

          -  Seropositivity for hepatitis B surface antigen, hepatitis C virus, or human
             immunodeficiency virus type 1 or type 2 antibodies.

          -  Symptoms of a clinically relevant illness within 3 weeks before the first trial day.

          -  History of or suspected drug or alcohol abuse.

          -  Subjects currently participating in another clinical study.

          -  Any investigational medicinal product administration within the last 4 weeks.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology - Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>February 4, 2010</firstreceived_date>
  <firstreceived_results_date>March 31, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Octaplas LG</keyword>
  <keyword>Octaplas SD</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Octaplas SD First, Then Octaplas LG</title>
          <description>Participants received 1200 mL of Octaplas SD intravenously once. At least 4 weeks later, participants received 1200 mL of Octaplas LG intravenously once.</description>
        </group>
        <group group_id="P2">
          <title>Octaplas LG First, Then Octaplas SD</title>
          <description>Participants received 1200 mL of Octaplas LG intravenously once. At least 4 weeks later, participants received 1200 mL of Octaplas SD intravenously once.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Enrolled in Study and Randomized</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Reason not Specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn by the Investigator</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population: All participants who received at least 1 of the study treatments in any study period.</population>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Participants received 1200 mL of Octaplas LG intravenously once and 1200 mL of Octaplas SD intravenously once in a crossover design.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="32.6" spread="9.11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recovery of the Coagulation Factors I, II, V, VII, VIII, IX, X, and XI</title>
        <description>Recovery was defined as the maximum percentage change of the coagulation factor value measured 5 minutes after the end of plasmapheresis to the coagulation factor value measured at 15 minutes or 2 hours after the end of study drug administration. The coagulation parameters were measured by validated assays from blood samples obtained 5 minutes after the end of plasmapheresis and 15 minutes and 2 hours after the end of study drug administration.</description>
        <time_frame>From 5 minutes after the end of plasmapheresis up to 2 hours after the end of study drug administration</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per protocol population: All participants who had evaluable efficacy measurements in both of the treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Octaplas LG</title>
            <description>Participants received 1200 mL of Octaplas LG intravenously once.</description>
          </group>
          <group group_id="O2">
            <title>Octaplas SD</title>
            <description>Participants received 1200 mL of Octaplas SD intravenously once.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Recovery of the Coagulation Factors I, II, V, VII, VIII, IX, X, and XI</title>
            <description>Recovery was defined as the maximum percentage change of the coagulation factor value measured 5 minutes after the end of plasmapheresis to the coagulation factor value measured at 15 minutes or 2 hours after the end of study drug administration. The coagulation parameters were measured by validated assays from blood samples obtained 5 minutes after the end of plasmapheresis and 15 minutes and 2 hours after the end of study drug administration.</description>
            <units>Percentage change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Factor I</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.11" spread="8.93"/>
                  <measurement group_id="O2" value="9.12" spread="8.75"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Factor II</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.08" spread="6.46"/>
                  <measurement group_id="O2" value="6.68" spread="7.35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Factor V</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.31" spread="9.35"/>
                  <measurement group_id="O2" value="6.91" spread="10.09"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Factor VII</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.48" spread="11.03"/>
                  <measurement group_id="O2" value="9.28" spread="14.53"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Factor VIII</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.50" spread="9.38"/>
                  <measurement group_id="O2" value="5.21" spread="9.93"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Factor IX</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.86" spread="9.11"/>
                  <measurement group_id="O2" value="11.08" spread="7.74"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Factor X</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.90" spread="8.96"/>
                  <measurement group_id="O2" value="9.97" spread="12.37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Factor XI</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.53" spread="6.32"/>
                  <measurement group_id="O2" value="8.24" spread="7.54"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Recovery of the Haemostatic Parameters Prothrombin Time, Activated Partial Thromboplastin Time, and Protein C</title>
        <description>Recovery was defined as the maximum (minimum for activated partial thromboplastin time) percentage change of the haemostatic parameter value measured 5 minutes after the end of plasmapheresis to the haemostatic parameter value measured at 15 minutes or 2 hours after the end of study drug administration. The haemostatic parameters were measured by validated assays from blood samples obtained 5 minutes after the end of plasmapheresis and 15 minutes and 2 hours after the end of study drug administration.</description>
        <time_frame>From 5 minutes after the end of plasmapheresis up to 2 hours after the end of study drug administration</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per protocol population: All participants who had evaluable efficacy measurements in both of the treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Octaplas LG</title>
            <description>Participants received 1200 mL of Octaplas LG intravenously once.</description>
          </group>
          <group group_id="O2">
            <title>Octaplas SD</title>
            <description>Participants received 1200 mL of Octaplas SD intravenously once.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Recovery of the Haemostatic Parameters Prothrombin Time, Activated Partial Thromboplastin Time, and Protein C</title>
            <description>Recovery was defined as the maximum (minimum for activated partial thromboplastin time) percentage change of the haemostatic parameter value measured 5 minutes after the end of plasmapheresis to the haemostatic parameter value measured at 15 minutes or 2 hours after the end of study drug administration. The haemostatic parameters were measured by validated assays from blood samples obtained 5 minutes after the end of plasmapheresis and 15 minutes and 2 hours after the end of study drug administration.</description>
            <units>Percentage change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Prothrombin time</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.36" spread="4.71"/>
                  <measurement group_id="O2" value="2.85" spread="6.18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Activated partial thromboplastin time</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-4.60" spread="3.71"/>
                  <measurement group_id="O2" value="-5.73" spread="4.39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Protein C</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.49" spread="8.44"/>
                  <measurement group_id="O2" value="9.75" spread="6.97"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Plasmin Inhibitor</title>
        <description>Values of plasmin inhibitor were measured by validated assays from blood samples obtained 30 minutes before plasmapheresis, 5 minutes after the end of plasmapheresis, 15 minutes and 2 hours after the end of study drug administration, and 24 hours and 7 days after initiation of plasmapheresis. The concentration of plasmin inhibitor is reported as the percentage of plasmin inhibition. A higher concentration of plasmin inhibitor results in a higher percentage of plasmin inhibition.</description>
        <time_frame>From 30 minutes before plasmapheresis up to 24 hours after the end of plasmapheresis</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per protocol population: All participants who had evaluable efficacy measurements in both of the treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Octaplas LG</title>
            <description>Participants received 1200 mL of Octaplas LG intravenously once.</description>
          </group>
          <group group_id="O2">
            <title>Octaplas SD</title>
            <description>Participants received 1200 mL of Octaplas SD intravenously once.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Concentration of Plasmin Inhibitor</title>
            <description>Values of plasmin inhibitor were measured by validated assays from blood samples obtained 30 minutes before plasmapheresis, 5 minutes after the end of plasmapheresis, 15 minutes and 2 hours after the end of study drug administration, and 24 hours and 7 days after initiation of plasmapheresis. The concentration of plasmin inhibitor is reported as the percentage of plasmin inhibition. A higher concentration of plasmin inhibitor results in a higher percentage of plasmin inhibition.</description>
            <units>Percentage inhibition</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Pre-plasmapheresis 30 minutes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="90.51" spread="9.93"/>
                  <measurement group_id="O2" value="91.53" spread="9.12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post-plasmapheresis 5 minutes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="85.72" spread="9.34"/>
                  <measurement group_id="O2" value="85.67" spread="10.08"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post-transfusion 15 minutes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="79.81" spread="8.15"/>
                  <measurement group_id="O2" value="74.93" spread="8.72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post-transfusion 2 hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="79.21" spread="8.45"/>
                  <measurement group_id="O2" value="75.23" spread="9.11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post-plasmapheresis 24 hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="88.35" spread="9.41"/>
                  <measurement group_id="O2" value="85.40" spread="8.93"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post-plasmapheresis 7 days</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="90.95" spread="9.79"/>
                  <measurement group_id="O2" value="91.65" spread="9.88"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety population: All participants who received at least 1 of the study treatments in any study period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Octaplas LG</title>
          <description>Participants received 1200 mL of Octaplas LG intravenously once.</description>
        </group>
        <group group_id="E2">
          <title>Octaplas SD</title>
          <description>Participants received 1200 mL of Octaplas SD intravenously once.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Eppolito, Director, Clinical Operations Immunology and ICU Medicine</name_or_title>
      <organization>Octapharma USA</organization>
      <phone>201 604-1155</phone>
      <email>michael.eppolito@octapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
